|
**Overview**: Methylenetetrahydrofolate Reductase Mutation (MTHFR Mutation) Panel**Introduction**: The MTHFR Mutation Panel is a diagnostic tool designed to screen for MTHFR mutations using whole blood samples. In India, MTHFR C677T and A1298C polymorphisms are common (~10-20 percent homozygous C677T in certain populations), associated with hyperhomocysteinemia, recurrent pregnancy loss, neural tube defects, and thrombophilia risk. High morbidity from over-testing/misinterpretation in rural/low-SES women with miscarriages or young patients with stroke, limited genetic labs, unnecessary folate supplementation or anxiety. Per genetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for C677T and A1298C mutations over 1-2 days with high accuracy, valuable for risk stratification in thrombophilia or NTD families. This diagnostic falls under genetic screening and targets patients with recurrent miscarriage, VTE, or NTD history, addressing accurate detection to guide high-dose folic acid or anticoagulation. With elevated burden from misuse, the test supports public health efforts by enabling evidence-based counseling and reducing unnecessary interventions. Its whole blood-based approach ensures reliable SNP detection.**Other Names**: MTHFR Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: MTHFR testing controversial but used in high-risk cases; in India, common in infertility/thrombophilia workup.**Purpose**: The test assesses 2 parameters including MTHFR C677T mutation to guide thrombophilia screening, detect risk alleles, inform folate therapy.**Test Parameters**: 1. MTHFR C677T Mutation, 2. MTHFR A1298C Mutation.**Pretest Condition**: No fasting required; patients should have thrombophilia or miscarriage history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on miscarriage, thrombosis, family NTD.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of misinterpretation including unnecessary treatment, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Homozygous C677T increases homocysteine risk; heterozygous mild, necessitating specialist input.**Specialist Consultation**: Hematologists or geneticists should be consulted for management.**Additional Supporting Tests**: Homocysteine, folate for confirmation.**Test Limitations**: Limited clinical utility; comprehensive approach required.**References**: Indian Journal of Human Genetics 2024, Thrombophilia Studies India 2023. |
